Ranbaxy Mulls Sale Of Lipitor Generic Rights If U.S. FDA Delays
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories said a delay in U.S. approval of its generic version of Pfizer's best-selling anti-cholesterol Lipitor (atorvastatin) might cause it to sell rights to another firm